June 26 (Reuters) - Novo Nordisk said on

Thursday it will collaborate with WeightWatchers to sell its

blockbuster weight-loss drug, Wegovy, starting July 1.

Under the deal, cash-paying patients can access a month's

supply of Wegovy through the Danish drugmaker's Novocare

pharmacy for $299. The one-time price will also be available

through Novo's other telehealth partners through July 31, the

company said in a release.

Novo recently announced the end of its collaboration with

Hims and Hers Health ( HIMS ), citing the telehealth platform's

sales of Wegovy copies and marketing tactics.

WeightWatchers, which is set to exit bankruptcy, no longer

offers compounded versions of semaglutide, the active ingredient

in Wegovy and other Novo Nordisk medicines, according to the

company's website.

"We will continue to pursue and build on agreements with

companies that share our values and refine initiatives that help

improve access to our FDA-approved medicines for patients," said

Dave Moore, an executive vice president at Novo Nordisk, adding

that it is in talks with other potential partners.

Novo said it is maintaining deals with Ro and LifeMD ( LFMD )

, rivals to WeightWatchers.